HER-Vaxx has completed Ph2 clinical trial with very good end result released and PD1-Vaxx is in Ph2 clinical trial, these are the IP that IMU has mentioned will be licensed to provide funds to advance their development and yes we are aware they will need a CR, likely mid next year or later if they can receive the $20M R&D rebate for last financial year.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)